2026-06-29T02:42:06Zhttps://docta.ucm.es/rest/oai/request

oai:docta.ucm.es:20.500.14352/1258272025-11-07T01:11:23Zcom_20.500.14352_14col_20.500.14352_15

00925njm 22002777a 4500 dc Boscia, A. author Galizzi, A. author Caccia, M. author Caroli, V. author Ortiz Díez, Gustavo author Toschi Corneliani, R. author Spalla, I. author 2025 Introduction/objectives: In dogs with myxomatous mitral valve disease (MMVD) American College of Veterinary Internal Medicine (ACVIM) stage D, hydrochlorothiazide (HCTZ) can be added to achieve sequential nephron blockade. Information on outcome, survival, and complications in this group of patients receiving HCTZ is limited, hence the aim of the present retrospective observational, longitudinal study. Animals, materials and methods: A single-referral-center cohort study was conducted; 25 dogs diagnosed with MMVD stage D receiving HCTZ as part of multimodal treatment of refractory congestive heart failure were included in the study. Data retrieved included cardiac treatment at T0 (when HCTZ was first prescribed) and subsequent visits, available bloodwork, echocardiographic assessment, additional diagnostics, cause of death, and survival time. Results: Mean starting dose of HCTZ was 0.8 mg/kg every 48 h, with progressive increases (latest mean recorded HCTZ dose: 1.5 mg/kg/day). Azotemia was identified in three dogs at T0 and in 11 dogs following HCTZ addition. Three dogs experienced clinically relevant side effects, resulting in discontinuation of HCTZ in one dog. Twenty dogs died, the majority due to cardiac disease (90). Median survival time of the cohort was 268 days. Study limitations: Limitations of this study included the retrospective nature of the study and small sample size. Conclusions: Although associated with an increase in renal parameters, HCTZ addition at the study dosages appeared clinically tolerated in most dogs with MMVD ACVIM stage D, with a prolonged median survival time for dogs in ACVIM stage D Boscia, A., Galizzi, A., Caccia, M., Caroli, V., Ortiz Diez, G., Toschi Corneliani, R., & Spalla, I. (2025). Retrospective review of the use of hydrochlorothiazide in dogs with myxomatous mitral valve disease and refractory congestive heart failure (American College of Veterinary Cardiology stage D). Journal of veterinary cardiology : the official journal of the European Society of Veterinary Cardiology, 62, 152–163. Advance online publication. https://doi.org/10.1016/j.jvc.2025.09.005 1760-2734 10.1016/j.jvc.2025.09.005 https://hdl.handle.net/20.500.14352/125827 1875-0834 https://doi.org/10.1016/j.jvc.2025.09.005 41129861 Retrospective review of the use of hydrochlorothiazide in dogs with myxomatous mitral valve disease and refractory congestive heart failure (American College of Veterinary Cardiology stage D)